Institutional Investors Lead Shift in Biomerica Inc (BMRA) Sentiment

Biomerica, Inc. (NASDAQ:BMRA) Logo

Sentiment for Biomerica Inc (BMRA)

Biomerica Inc (BMRA) institutional sentiment decreased to 1 in Q2 2019. Its down -0.50, from 1.5 in 2019Q1. The ratio dropped, as 4 investment professionals started new and increased equity positions, while 4 decreased and sold their stakes in Biomerica Inc. The investment professionals in our partner’s database now hold: 120,162 shares, down from 125,183 shares in 2019Q1. Also, the number of investment professionals holding Biomerica Inc in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 2 Reduced: 2 Increased: 1 New Position: 3.

Biomerica, Inc., together with its subsidiaries, develops, makes, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions worldwide. The company has market cap of $30.28 million. The companyÂ’s diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; and to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It currently has negative earnings. It primarily focuses on products for gastrointestinal, food intolerances, diabetes, and esoteric tests.

The stock increased 1.64% or $0.05 during the last trading session, reaching $3.1. About 16,686 shares traded. Biomerica, Inc. (BMRA) has declined 7.84% since September 13, 2018 and is downtrending. It has underperformed by 7.84% the S&P500.

Analysts await Biomerica, Inc. (NASDAQ:BMRA) to report earnings on October, 15. They expect $-0.08 EPS, down 60.00 % or $0.03 from last year’s $-0.05 per share. After $-0.08 actual EPS reported by Biomerica, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Perritt Capital Management Inc holds 0.04% of its portfolio in Biomerica, Inc. for 40,000 shares. Bard Associates Inc owns 10,000 shares or 0.01% of their US portfolio. Moreover, Bank Of America Corp De has 0% invested in the company for 4,361 shares. The New York-based Blackrock Inc. has invested 0% in the stock. Heritage Investors Management Corp, a Maryland-based fund reported 15,550 shares.

More notable recent Biomerica, Inc. (NASDAQ:BMRA) news were published by: Benzinga.com which released: “Want Consistency? Learn To Scalp – Benzinga” on April 12, 2019, also Globenewswire.com with their article: “Biomerica Reports 1st Quarter Fiscal 2019 Financials Nasdaq:BMRA – GlobeNewswire” published on October 16, 2018, Nasdaq.com published: “Health Care Sector Update for 08/30/2019: AAC, PRTK, QHC, CYH – Nasdaq” on August 30, 2019. More interesting news about Biomerica, Inc. (NASDAQ:BMRA) were released by: Globenewswire.com and their article: “Biomerica Announces Second Quarter Financial Results; Sales Up 12.7% for the Quarter – GlobeNewswire” published on January 16, 2018 as well as Globenewswire.com‘s news article titled: “Biomerica signs exclusive distribution agreement in China for its colorectal screening test with total minimum purchase requirement of $17 million over 7 years and an upfront pre-payment of $1 million. – GlobeNewswire” with publication date: June 05, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.